Amlexanox / TTA (40/200 mg), Oral
New products not causing hyperactivity Increases weight loss by activating genes. (2-10 pounds lost in 12 weeks without diet or exercise) Human studies.
Increased fat utilization to reverse obesity by activating genes that increase fat metabolism in animals.
notes: Amlexanox has been shown in human studies to decrease body weight 4-10 pounds (1-6%). Amlexanox is an FDA approved drug used to treat painful mouth ulcers.
Tetradecyl Thioacetic Acid
Technically an Omega-3 fatty acid, TTA is a non-metabolizable fatty acid that cannot be used for energy and may be able to burn fat via mechanisms similar to Conjugated Linoleic Acid. CLA are fatty acids that acts on a system known as PPAR to induce fat loss. At least, that is what the theory says. CLA too weakly affects PPAR receptors to really induce fat loss in an appreciable amount. TTA appears more promising.
Many people have trouble actually losing weight despite diet and exercise. Vie has products that may help and are listed below:
5 Amino-1MQ: Promotes fat breakdown by blocking NNMT. (7% loss of weight, 30 % loss of fat in 10 days) Mouse studies.
Amlexanox/TTA: Increases weight loss by activating genes. (2-10 pounds lost in 12 weeks withhout diet or exercise) Human studies.
Tesofensine: Increases availability of norepinephrine (energy/ alertness), dopamine (pleasure), and serotonin (mood) and decreases appetite. (28-32 pounds in 24 weeks) Human studies.
Tesamorelin: Increases GH secretion for visceral (intestine and liver) fat loss.(15.2% at 26 weeks) Human studies. FDA approved. 7 Keto DHEA: Weight loss without effort. Endorsed by Dr. Oz
Increases BMR,increases thyroid, and blocks cortisol. (6.6 pounds weight loss over 8 weeks) Human Studies.
methyl B-12: Improves mood, energy, and metabolism to promote weight loss. Safe and investigated by many human studies. Also helps with stress management. Commonly used in weight loss clinics.
MIC + mB12: The MIC amino acid combination is used at weight loss clinics to help your body eliminate fat when you diet and exercise.
GOAL: This 4 amino acid combination stimulates the body to increase its growth hormone secretion to improve your energy, build muscle, and decrease fat. This is commonly used at weight loss clinics to help patients lose weight.
Summary: A research team at UCSD discovered a key enzyme that plays a role in burning calories during both obesity and dieting and sabotages weight loss. Moreover, these scientists may have just found an existing drug that counteracts this enzyme.
Doctors will begin testing amlexanox in humans later this year.
Study: Obese mice given a canker sore drug lost weight without cutting calories, moving more
Doctors will begin testing the drug, amlexanox, in humans later this year
If the drugs works, it could be like Viagra, which originally wa meant to treat chest pain
A relatively obscure drug used to treat mouth sores has made obese mice thin — and the mice didn’t have to eat less or exercise more, according to a study at the University of Michigan.
Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes
- 12 weeks amlexanox treatment significantly reduced HbA1c in obese diabetic subjects
- amlexanox treatment did not affect all subjects equally
- the amlexanox treated responders had higher baseline inflammation
- energy expenditure-associated genes were increased in responders
- Statistically significant weight loss was observed during the 12-week amlexanox treatment: 4-11 pounds or 1-6% body weight
Numerous studies indicate an inflammatory link between obesity and type 2 diabetes. The inflammatory kinases IKKε and TBK1 are elevated in obesity; their inhibition in obese mice reduces weight, insulin resistance, fatty liver and inflammation. Here we studied amlexanox, an inhibitor of IKKε/TBK1, in a proof-of-concept randomized, double
blind, placebo-controlled study of 42 obese patients with type 2 diabetes and nonalcoholic fatty liver disease. Treatment of patients with amlexanox produced a statistically significant reduction in Hemoglobin A1c and fructosamine. Interestingly, a subset of drug responders also exhibited improvements in insulin sensitivity and hepatic steatosis. This subgroup was characterized by a distinct inflammatory gene expression signature from biopsied subcutaneous fat at baseline. They also exhibited a unique pattern of gene expression changes in response to amlexanox, consistent with increased energy expenditure. Together, these data suggest that IKKε/TBK1 inhibitors may be effective therapies for metabolic disease in an identifiable subset of patients.